Trials Offered by a Specific Doctor

Matthew Ingham, MD
Dr. Ingham is Assistant Professor of Medicine in the Division of Hematology and Oncology at New York Presbyterian Hospital/Columbia University Medical Center. He received his medical degree from the University of Massachusetts Medical School and completed internship and residency training in Internal Medicine at New York University Medical Center, where he served as Chief Resident. He then completed fellowship training in Hematology and Medical Oncology at New York Presbyterian Hospital/Columbia University Medical Center where he served as Chief Fellow.

Dr. Ingham specializes in the care of patients with sarcoma and gastrointestinal cancers and is also an active member of the experimental therapeutics unit. His research focuses on the development and clinical evaluation of new treatments for patients with sarcoma. He leads a National Cancer Institute (NCI) sponsored clinical trial evaluating a new treatment approach for uterine leiomyosarcoma based on research conducted at Columbia University. He also leads several other investigator-initiated clinical trials evaluating new targeted and immunotherapy based treatment approaches for leiomyosarcoma, liposarcoma and other types of sarcoma. He is the author of two recent authoritative reviews on the treatment of sarcoma published in the Journal of Clinical Oncology. He is the recipient of the 2019 Conquer Cancer Foundation of ASCO Career Development Award from the Sarcoma Foundation of America in recognition of his research and was also named a 2019 NextGen Innovator by HemOnc Today, among other awards and honors. His overall goal is to provide patients with compassionate oncologic care and access to the most promising treatment approaches.

Clinical Studies Managed By Dr. Ingham:
More InfoTitleSponsorIRB Number
Details[CLOSED] A study for patients with AML, MDS, Myelofibrosis or solid tumors using study drug INCB059872Incyte CorporationAAAQ7418
DetailsA study for patients with sarcoma using study drug MGCD516Mirati TherapeuticsAAAQ8661
DetailsA study for patients with advanced solid tumors or lymphomas using study drug MK-1454Merck Sharp & Dohme Corp.AAAR1107
DetailsCollecting and growing patient tumor and blood cells from extra tissue to learn about cancer and test new drugsNational Cancer Institute NCIAAAP6710
Details[CLOSED] INVICTUS Study of Drug in Advanced Gastrointestinal Stromal TumorsDeciphera Pharmaceuticals, LLCAAAR6045
DetailsEarly Onset Malignancies Initiative (EOMI)NCI NCORPAAAR3353
DetailsStudy of Drug (MK-2118) in Patients with Solid Tumors or LymphomasMerckAAAR4398
DetailsStudy of MIW815 (ADU-S100) in Patients with Advanced/Metastatic Solid Tumors or LymphomasNovartis and Aduro BiotechAAAR6676
DetailsA Study of AL3818 (Anlotinib) in Patients with Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial SarcomaAdvenchen Laboratories, LLC.AAAS0001
DetailsA Study of the Addition of APX005M to Doxorubicin in Patients with Advanced SarcomaApexigenAAAS0095
DetailsA Study of BA3021 in Patients with Advanced Solid Tumors (Lung Cancer, Triple Negative Breast Cancer, or Soft Tissue Sarcoma)BioAtla LLCAAAS0590
DetailsA Study of PTC596 in Combination With Dacarbazine in Participants With Advanced Leiomyosarcoma (LMS)PTC Therapeutics, Inc.AAAS2818
DetailsSelinexor in Combination With Ixazomib for the Treatment of Advanced SarcomaMatthew Ingham, MDAAAS0199
DetailsStudy of Talimogene Laherparepvec (T-VEC) and Radiation in Soft Tissue SarcomaNIHAAAS2351
DetailsStudy of Intratumorally Administered INT230-6 in Adult Subjects with Solid TumorsIntensity TherapeuticsAAAS1193
DetailsStudy of Olaparib in Combination with Temozolomide for the Treatment of Advanced Uterine LeiomyosarcomaNIHAAAS4040
DetailsStudy of BA3011 in Subjects with Advanced Solid TumorsBioAtla LLCAAAS7054